Amneal Pharmaceuticals (AMRX) Profit After Tax (2017 - 2026)

Amneal Pharmaceuticals' Profit After Tax history runs 10 years deep, the most recent figure standing at $62.3 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 410.5% year-over-year to $62.3 million in Q1 2026; TTM through Mar 2026 was $136.6 million, a 504.11% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 209.45% from the prior year.
• Profit After Tax rose to $62.3 million in Q1 2026 per AMRX's latest filing, from $49.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at $62.3 million in Q1 2026 and bottomed at -$240.1 million in Q2 2022.
• The 5-year median for Profit After Tax is $3.8 million (2022), against an average of -$18.1 million.
• Across the five-year window, Profit After Tax tumbled 2717.38% in 2023 and surged 410.5% in 2026, its largest moves.
• Year by year, Profit After Tax stood at $3.8 million in 2022, then tumbled by 2717.38% to -$98.6 million in 2023, then surged by 35.37% to -$63.8 million in 2024, then soared by 177.76% to $49.6 million in 2025, then climbed by 25.58% to $62.3 million in 2026.
• Per Business Quant, the three latest AMRX Profit After Tax figures stand at $62.3 million (Q1 2026), $49.6 million (Q4 2025), and $2.4 million (Q3 2025).